Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor ‒Positive/Human Epidermal Growth Factor Receptor 2‒Negative Advanced Breast Cancer.

CONCLUSIONS: Pembrolizumab was well-tolerated with modest but durable objective response in certain patients with previously treated, advanced, PD-L1‒positive, ER+/HER2- breast cancer. PMID: 29559561 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29559561?dopt=Abstract

Source: Clinical Genitourinary Cancer - March 20, 2018 Category: Cancer & Oncology Authors: Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR Tags: Clin Cancer Res Source Type: research